July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Three-year Outcomes of Treat and Extend Aflibercept Treatment for Neovascular Age-related Macular Degeneration
Author Affiliations & Notes
  • Keiko Kataoka
    Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi-prefecture, Japan
  • Keiko Asai
    Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi-prefecture, Japan
  • Yuma Tsunekawa
    Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi-prefecture, Japan
  • Yasuki Ito
    Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi-prefecture, Japan
  • Hiroko Terasaki
    Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi-prefecture, Japan
  • Footnotes
    Commercial Relationships   Keiko Kataoka, Alcon Pharma (R), Bayer Health Care (R), Santen Pharmaceutical (R); Keiko Asai, None; Yuma Tsunekawa, None; Yasuki Ito, Alcon Pharma (R), Bayer Health Care (R), Canon Life Care Solutions Inc. (R), Carl Zeiss Meditec Co. (R), Kowa Pharmaceutical Company (R), Santen Pharmaceutical Co (R); Hiroko Terasaki, AbbVie GK (R), Alcon Pharma (F), AMO Japan (F), Bayer Health Care (F), Carl Zeiss Meditec Co. (R), DAIICHI SANKYO (C), Eisai Co. (F), HOYA Corporation Ltd. (F), Kowa Pharmaceutical Company (F), Mitsubishi Tanabe Pharma (R), NIDEK (F), Nitten Pharmaceutical Co. (R), Otsuka Pharmaceutical Co. (F), Pfizer Japan (F), Sanofi K.K. (R), Santen Pharmaceutical Co. (F), Senju Pharmaceutical Co. (F), Tomey Corporation (F), WAKAMOTO Co. (F)
  • Footnotes
    Support  JSPS KAKENHI Grant Number 18K16953
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 81. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keiko Kataoka, Keiko Asai, Yuma Tsunekawa, Yasuki Ito, Hiroko Terasaki; Three-year Outcomes of Treat and Extend Aflibercept Treatment for Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2019;60(9):81. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate 3-year treatment outcomes with aflibercept treat and extend (TAE) regimen for neovascular age-related macular degeneration (nAMD).

Methods : This retrospective study included eyes diagnosed with nAMD from January 2013 to September 2015. All the eyes were treated with aflibercept treatment at least 3 years. LogMAR Best-corrected visual acuity (BCVA) and injection numbers, as well as age, sex, subtypes of nAMD such as typical AMD, polypoidal choroidal vasculopathy, and type 3 neovascularization, were analyzed.

Results : Total 61 eyes of 61 patients were available at 3-year follow-up data. The mean (±S.D.) age was 75.0 ± 7.1 years. Of total 61 eyes of 61 patients, 27 eyes were treatment-naïve (group 1), 15 eyes had past history of anti-vascular endothelial growth factor (VEGF) therapies (group 2), and the rest of 19 eyes had past history of photodynamic therapy (PDT) (group 3). The mean BCVA in the group 1 significantly improved from 0.26 ± 0.23 at the baseline to 0.12 ± 0.16 at 1 year, 0.14 ± 0.26 at 2 years, and 0.14 ± 0.22 at 3 years, respectively. The mean BCVA in the group 2 at baseline, 1, 2, and 3 years were 0.22 ± 0.24, 0.14 ± 0.18, 0.18 ± 0.19, and 0.16 ± 0.19, and those in the group 3 were 0.35 ± 0.26, 0.34 ± 0.25, 0.35 ± 0.30, and 0.37 ± 0.35. There was no significant improvement nor worsening in the BCVA during the follow-up periods in the group 2 and 3. For the comparisons among the three groups, there was no significant difference in age, sex, subtypes of AMD, and the baseline BCVA. However, the BCVA in the group 1 at 1, 2, and 3 years were significantly better than those in the group 3 (P = 0.001, P = 0.025, and P = 0.011, respectively). Annual mean injection numbers in the first, second, and third year were 6.4 ± 1.7, 7.8 ± 2.3, and 5.0 ± 2.5 in the group 1; 7.6± 2.3, 6.4 ± 2.3, and 5.8 ± 2.4 in the group 2; and 6.8 ± 1.9, 4.9 ± 1.9, and 4.7 ± 2.3 in the group 3. There was no significant difference in injection numbers at 1, 2, and 3 years among the three groups.

Conclusions : Aflibercept TAE treatment for nAMD could keep long-term visual acuity in a clinical setting. Notably, this treatment is favorable for eyes with treatment-naïve nAMD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×